Press Releases Year None20212020201920182017201620152014 May 6, 2021 Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program May 5, 2021 New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test May 4, 2021 Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S. April 30, 2021 Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness Month April 27, 2021 Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory April 26, 2021 Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021 April 23, 2021 Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population April 22, 2021 Castle Biosciences Presents Data at the Dermatology Nurses’ Association 2021 Annual Convention April 16, 2021 Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress April 15, 2021 Late-Breaking New Independent Validation Study of 1,674 Patients Demonstrates Castle Biosciences' i31-GEP Artificial Intelligence Algorithm Improves Precision of Sentinel Lymph Node Positivity Prediction in Cutaneous Melanoma April 14, 2021 Largest, Independent, Prospective Study Demonstrates Utility of DecisionDx®-Melanoma for Prediction of Outcomes in Patients With Cutaneous Melanoma Referred for Sentinel Node Biopsy April 13, 2021 Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma April 1, 2021 Castle Biosciences Collaborates with the Melanoma Research Foundation for “Ask the Expert” Live Webinar Series with Melanoma Experts March 29, 2021 Castle Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference March 25, 2021 Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions March 8, 2021 Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results March 8, 2021 Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk February 22, 2021 Castle Biosciences to Release Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Monday, March 8, 2021 February 8, 2021 Castle Biosciences to Present at Upcoming Investor Conferences February 4, 2021 Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach Symposium January 20, 2021 Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference January 13, 2021 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results January 4, 2021 Castle Biosciences to Present at the 23rd Annual Needham Virtual Growth Conference
Press Releases Year None20212020201920182017201620152014 May 6, 2021 Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program May 5, 2021 New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test May 4, 2021 Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S. April 30, 2021 Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness Month April 27, 2021 Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory April 26, 2021 Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021 April 23, 2021 Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population April 22, 2021 Castle Biosciences Presents Data at the Dermatology Nurses’ Association 2021 Annual Convention April 16, 2021 Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress April 15, 2021 Late-Breaking New Independent Validation Study of 1,674 Patients Demonstrates Castle Biosciences' i31-GEP Artificial Intelligence Algorithm Improves Precision of Sentinel Lymph Node Positivity Prediction in Cutaneous Melanoma April 14, 2021 Largest, Independent, Prospective Study Demonstrates Utility of DecisionDx®-Melanoma for Prediction of Outcomes in Patients With Cutaneous Melanoma Referred for Sentinel Node Biopsy April 13, 2021 Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma April 1, 2021 Castle Biosciences Collaborates with the Melanoma Research Foundation for “Ask the Expert” Live Webinar Series with Melanoma Experts March 29, 2021 Castle Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference March 25, 2021 Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions March 8, 2021 Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results March 8, 2021 Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk February 22, 2021 Castle Biosciences to Release Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Monday, March 8, 2021 February 8, 2021 Castle Biosciences to Present at Upcoming Investor Conferences February 4, 2021 Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach Symposium January 20, 2021 Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference January 13, 2021 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results January 4, 2021 Castle Biosciences to Present at the 23rd Annual Needham Virtual Growth Conference
May 6, 2021 Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program
May 5, 2021 New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test
May 4, 2021 Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.
April 30, 2021 Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness Month
April 26, 2021 Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021
April 23, 2021 Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population
April 22, 2021 Castle Biosciences Presents Data at the Dermatology Nurses’ Association 2021 Annual Convention
April 16, 2021 Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress
April 15, 2021 Late-Breaking New Independent Validation Study of 1,674 Patients Demonstrates Castle Biosciences' i31-GEP Artificial Intelligence Algorithm Improves Precision of Sentinel Lymph Node Positivity Prediction in Cutaneous Melanoma
April 14, 2021 Largest, Independent, Prospective Study Demonstrates Utility of DecisionDx®-Melanoma for Prediction of Outcomes in Patients With Cutaneous Melanoma Referred for Sentinel Node Biopsy
April 13, 2021 Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma
April 1, 2021 Castle Biosciences Collaborates with the Melanoma Research Foundation for “Ask the Expert” Live Webinar Series with Melanoma Experts
March 29, 2021 Castle Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference
March 25, 2021 Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions
March 8, 2021 Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk
February 22, 2021 Castle Biosciences to Release Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Monday, March 8, 2021
February 4, 2021 Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach Symposium
January 20, 2021 Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference
